Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 7.3 %

Shares of NASDAQ EGRX opened at $3.96 on Wednesday. Eagle Pharmaceuticals has a twelve month low of $3.21 and a twelve month high of $15.91. The stock has a 50 day moving average of $4.70 and a two-hundred day moving average of $4.74. The stock has a market cap of $51.43 million, a P/E ratio of 3.36 and a beta of 0.53.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new position in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $145,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $65,000. Perceptive Advisors LLC acquired a new position in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $971,000. Mackenzie Financial Corp acquired a new position in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $60,000. Finally, Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals during the second quarter worth $71,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.